Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
DOXORUBICIN

DOXORUBICIN

Send Inquiry
Sub Group Generic Formulary Brand Name Dosages Unit In treatment of Adverse Effects Contraindication Special Precaution Interaction Servings

DOXORUBICIN Adriamycin PFS, Adriamycin RDF ,Rubex 10 mg/50 mg Vial Treatment of Metastatic Braeast Carcinoma 1. Nausea
2. Vomiting
3. Loss of appetite
4. Diarrhea
5. Difficulty in swallowing
6. Brittle hair
7. Skin irritation
8. Rash
9. Swelling
10. Pain
11. Redness
12. Peeling of the skin on the palms and soles of the feet.
13. Tarry stools
14. Cough
15. Chills
16. Facial swelling
17. Bruising or unusual bleeding
18. Weakness
19. Blood in urine or stools
20. Constipation
21. Anxiety
22. Burning
23. Itching eyes
24. Change in taste
25. Muscle ache
26. Swelling of eyes and eyelid
27. Trouble sleeping
28.Irreversible cardiomyopathy
29.Arrhythmia
30.Left ventricular failure
1. Thrombocytopenia
2. Severe leucopenia
3. Myelosuppression
4. Previous treatment with antitumor agent or by radiotherapy
5. Cardiac disease
1. Hyper sensitivity to other neoplastic drugs
2. Kidney diseases
3. Renal diseases
4. Recent Immunization
Mercaptopurine: Hepatotoxicity of mercaptopurine enhanaced leading to cholestasis.
Cyclophosphamide: Exacerbation of cyclophosphamide induced hemorrhagic cystitis.
Barabiturates: Increase the plasma clearance of doxorubicin.
Digoxin: Decreased serum levels of digoxin.
Streptozotocin: Increases toxicity of doxorubicin.
Radiation: Radiation induced toxicity to myocardium, mucosa, skin and liver increased.
Intravenous-
Adult-
60 to 75 mg/metre square single dose every 21 days
30mg/metre square daily every 3 days.